Product Information
VENLAFAXINE HCL ER 37.5 MG TAB is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.3581 per EA under NDC 64980057809. Its NADAC has been published 147 times since Dec 13, 2023.
FDA first approved this application on Nov 28, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
37.5 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
64980057809
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
VENLAFAXINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA216044FDA Approved
11/28/2022
TE Code
AB
On Market Since
11/28/2022
Pharmacological Classes
Price Statistics
The NADAC for VENLAFAXINE HCL ER 37.5 MG TAB has been published 147 times since Dec 13, 2023, and over the history we have for it it has declined 57.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3581 per EA |
|---|---|
| All-time high | $1.1576 (Apr 10, 2024) |
| All-time low | $0.3039 (Jan 22, 2025) |
| 52-week high | $0.6187 |
| 52-week low | $0.3302 |
| Median price | $0.4754 |
| Average price | $0.5125 |
| Largest weekly change | -56.8% (Apr 17, 2024) |
| Weeks tracked | 147 |
| Tracking since | Dec 13, 2023 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 80% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Venlafaxine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin and Norepinephrine Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VENLAFAXINE HCL ER 37.5 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for VENLAFAXINE HCL ER 37.5 MG TAB, manufactured by Rising Pharma Holdings Inc., is $0.3581 per EA (NDC 64980057809), effective Sep 30, 2026.
How has the price of VENLAFAXINE HCL ER 37.5 MG TAB changed over time?
Over the history we have for it, the NADAC for VENLAFAXINE HCL ER 37.5 MG TAB has declined 57.3%. It has been tracked across 147 weekly CMS publications since Dec 13, 2023.
What are the highest and lowest recorded NADAC prices for VENLAFAXINE HCL ER 37.5 MG TAB?
Since Dec 13, 2023, the NADAC for VENLAFAXINE HCL ER 37.5 MG TAB has ranged from a low of $0.3039 (Jan 22, 2025) to a high of $1.1576 (Apr 10, 2024), with a median of $0.4754 per EA.
Are there cheaper alternatives to VENLAFAXINE HCL ER 37.5 MG TAB?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, VENLAFAXINE HCL 37.5 MG TABLET, is $0.0714 per EA — about 80% below VENLAFAXINE HCL ER 37.5 MG TAB.
Who manufactures VENLAFAXINE HCL ER 37.5 MG TAB?
VENLAFAXINE HCL ER 37.5 MG TAB (NDC 64980057809) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.